<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01657292</url>
  </required_header>
  <id_info>
    <org_study_id>BBW-11</org_study_id>
    <secondary_id>2012-000362-38</secondary_id>
    <nct_id>NCT01657292</nct_id>
  </id_info>
  <brief_title>Oleogel-S10 Versus Standard of Care in Healing of Grade 2a Burn Wounds</brief_title>
  <official_title>Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 Versus Standard of Care in Accelerating the Healing of Grade 2a Partial-Thickness Burn Wounds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Birken AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amryt Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal of this phase III clinical trial is to show safety and efficacy of Oleogel-S10
      in the acceleration of wound healing of grade 2a burn wounds.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oleogel-S10 has shown efficacy and was well tolerated in previous clinical trials in patients
      with skin lesions. Especially the results in the split-thickness skin graft donor site, which
      is regarded as an excellent model for any kind of superficial wounds in human skin, suggest
      that Oleogel-S10 should be efficacious and safe in treatment of grade 2a burns.

      The present Phase III clinical trial in grade 2a burns is initiated in order to measure the
      wound healing progress applying objective methods, i.e., the time to healing and the grade of
      epithelialization of the wound.

      In this study, grade 2a burn wounds are separated into two halves: Following wound cleaning
      and disinfection, wounds are separated into two wound halves. Randomly assigned, one wound
      half receives Oleogel-S10 ointment, the other wound half standard of care treatment.

      Wound healing progress is documented by photos which are assessed by expert reviewers blinded
      to the treatment of the wound halves.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients With Earlier Healing of the Wound Half Treated With Oleogel-S10 Compared to the Wound Half Receiving Standard of Care</measure>
    <time_frame>2 to 3 weeks</time_frame>
    <description>Photo-based evaluation by independent experts blinded to the treatment regime.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intra-individual Difference in Time to Wound Closure Between Wound Halves, Either Treated With Oleogel-S10 or Treated With Standard of Care</measure>
    <time_frame>2 to 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Study Start After Burn Accident Until Wound Closure is Achieved Separately for Wound Halves Treated With Oleogel-S10 vs. Standard of Care</measure>
    <time_frame>2 to 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Wound Closure at Different Time Points</measure>
    <time_frame>2 to 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Wound Epithelialization at Different Time Points as Assessed by the Investigator</measure>
    <time_frame>2 to 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Likert Scale Rating of Efficacy (Evaluated by Both the Investigators and Patients)</measure>
    <time_frame>2 to 3 weeks</time_frame>
    <description>By direct comparison of the separate simultaneous treatments for the two wound halves, patients and investigators, respectively, are asked to grade the efficacy of Oleogel-S10 Versus Standard of Care on a questionnaire with a 5-point graded visual analogue scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cosmetic Outcome After 3 and 12 Months After Burn Accident, in Relation to Texture, Redness, Growth of Hair and Pigmentation, Based on Blinded Photo Evaluation</measure>
    <time_frame>3 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Likert Scale Rating of Tolerance (Evaluated by Both the Investigators and Patients)</measure>
    <time_frame>2 to 3 weeks</time_frame>
    <description>By direct comparison of the separate simultaneous treatments for the two wound halves, patients and investigators, respectively, are asked to provide their opinion on the tolerance of Oleogel-S10 Versus Standard of Care on a questionnaire with a 5-point graded visual analogue scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Data: Systemic Presence/Concentration of Betulin in Blood Plasma Samples</measure>
    <time_frame>2 to 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbial Colonization of the Wound Halves</measure>
    <time_frame>2 to 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Adverse Events</measure>
    <time_frame>2 to 3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Burns</condition>
  <arm_group>
    <arm_group_label>Oleogel-S10 ointment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-individual comparison. Oleogel-S10 ointment is administered to one randomly assigned wound half.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Octenilin® wound gel</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intraindividual comparison: The other wound half receives disinfectant Octenilin® wound gel.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oleogel-S10 ointment</intervention_name>
    <description>Intraindividual comparison: One randomly assigned wound half is treated with Oleogel-S10 ointment and fatty gauze wound dressing</description>
    <arm_group_label>Oleogel-S10 ointment</arm_group_label>
    <arm_group_label>Octenilin® wound gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Octenilin® wound gel</intervention_name>
    <description>Intraindividual comparison: The other wound half is treated with Octenilin® wound gel and fatty gauze wound dressing</description>
    <arm_group_label>Oleogel-S10 ointment</arm_group_label>
    <arm_group_label>Octenilin® wound gel</arm_group_label>
    <other_name>Contains Octenidine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients at least 18 years old who have provided written informed consent.

          -  Presenting with acute grade 2a burn wounds (as graded by an expert surgeon assisted by
             LDI or a multispectral imaging system) within 48 hours after injury.

          -  Burn wound caused by fire burn, heat burn or scalding.

          -  Burn patients with grade 2a burn wounds between 80 cm2 and less than 25% of their TBSA
             (alternatively, 2 comparable wounds with size more than 40 cm2 each and less than
             12.5% of the TBSA each are allowed).

          -  Patient is able to understand the Informed Consent Form provided and is prepared to
             comply with all study requirements, including the following: Visiting the trial site
             for wound dressing changes at least every second day (if patient is not hospitalized)
             and photo documentation until full wound closure or until the Investigator decides to
             change medication and/or treatment after day 21 after start of treatment

          -  Willing to perform all necessary wound dressing changes at the trial site. Also the
             patient needs to agree to return to site for 3 and 12 months follow-up visits.

          -  Women of childbearing potential must apply highly effective method of birth control
             (failure rate less than 1% per year when used consistently and correctly (e.g.,
             implants, injectables, combined oral contraceptives, some intrauterine contraceptive
             devices (IUDs), sexual abstinence, or a vasectomized partner))

        Exclusion Criteria:

          -  Suffering from chemical burns, or electrical burns or sunburns

          -  Having already received treatment for their burn with silver sulfadiazine (obscures
             photographic wound evaluation).

          -  Positive blood culture after the burn.

          -  Diseases or conditions that could, in the opinion of the Investigator, interfere with
             the assessment of safety, tolerance or efficacy.

          -  A skin disorder that is chronic or currently active and which the Investigator
             considers will adversely affect the healing of the acute wounds or involves the areas
             to be examined in this trial.

          -  A history of clinically significant hypersensitivity to any of the drugs or surgical
             dressings to be used in this trial.

          -  Known multiple allergic disorders.

          -  Taking, or have taken, any investigational drugs within 3 months prior to the
             screening visit.

          -  Pregnant or breast feeding women are not allowed to participate in the study.

          -  Inappropriate to participate in the study, for any reason, in the opinion of the
             Investigator.

          -  Mental incapacity or language barriers precluding adequate understanding or
             co-operation or willingness to follow study procedures.

          -  Previous participation in this study.

          -  Employee at the investigational site, relative or spouse of the Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernd Hartmann, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Trauma Hospital Berlin, Warener Str. 7, 12683 Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unfallkrankenhaus Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Broomfield Hospital</name>
      <address>
        <city>Chelmsford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Victoria Hospital</name>
      <address>
        <city>East Grinstead</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2012</study_first_submitted>
  <study_first_submitted_qc>August 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2012</study_first_posted>
  <results_first_submitted>July 31, 2015</results_first_submitted>
  <results_first_submitted_qc>August 28, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 28, 2015</results_first_posted>
  <last_update_submitted>August 28, 2015</last_update_submitted>
  <last_update_submitted_qc>August 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Wound healing</keyword>
  <keyword>Burn wound</keyword>
  <keyword>Superficial partial-thickness burn wound</keyword>
  <keyword>Grade 2a burn wounds</keyword>
  <keyword>Time to wound closure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study participants were enrolled from 31-Aug-2012 to 10-Jul-2013, in 10 clinical centres in 4 countries: Germany (4 centers), Uk (3 centers), Sweden (2 centers), and Switzerland (1 center).</recruitment_details>
      <pre_assignment_details>66 patients were screened of which 5 violated eligibility criteria and thus 61 subjects were treated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Entire Study Population</title>
          <description>All patients treated with Oleogel-S10 and Octenilin® wound gel.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Violation of eligibility criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Change of therapy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>All patients treated with Oleogel-S10 and Octenilin® wound gel.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="61"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" lower_limit="18" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With Earlier Healing of the Wound Half Treated With Oleogel-S10 Compared to the Wound Half Receiving Standard of Care</title>
        <description>Photo-based evaluation by independent experts blinded to the treatment regime.</description>
        <time_frame>2 to 3 weeks</time_frame>
        <population>The analysis included all patients who were treated at least once with Oleogel-S10 or Octenilin® wound gel (as randomised) and for whom a difference in wound healing between the treatment was observed.</population>
        <group_list>
          <group group_id="O1">
            <title>Entire Study Population</title>
            <description>All patients treated with Oleogel-S10 and Octenilin® wound gel.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Earlier Healing of the Wound Half Treated With Oleogel-S10 Compared to the Wound Half Receiving Standard of Care</title>
          <description>Photo-based evaluation by independent experts blinded to the treatment regime.</description>
          <population>The analysis included all patients who were treated at least once with Oleogel-S10 or Octenilin® wound gel (as randomised) and for whom a difference in wound healing between the treatment was observed.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7" lower_limit="69.7" upper_limit="95.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>All patients received both treatments and treatments were intra-individually compared.
Hypotheses tested: H0: s0 ≤0.5 and H1: s0 &gt;0.5 (with s0=rate of superiority of Oleogel-S10).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>1-sided, significance level = 0.025</p_value_desc>
            <method>Binomial test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intra-individual Difference in Time to Wound Closure Between Wound Halves, Either Treated With Oleogel-S10 or Treated With Standard of Care</title>
        <time_frame>2 to 3 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Study Start After Burn Accident Until Wound Closure is Achieved Separately for Wound Halves Treated With Oleogel-S10 vs. Standard of Care</title>
        <time_frame>2 to 3 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Wound Closure at Different Time Points</title>
        <time_frame>2 to 3 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Wound Epithelialization at Different Time Points as Assessed by the Investigator</title>
        <time_frame>2 to 3 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Likert Scale Rating of Efficacy (Evaluated by Both the Investigators and Patients)</title>
        <description>By direct comparison of the separate simultaneous treatments for the two wound halves, patients and investigators, respectively, are asked to grade the efficacy of Oleogel-S10 Versus Standard of Care on a questionnaire with a 5-point graded visual analogue scale</description>
        <time_frame>2 to 3 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cosmetic Outcome After 3 and 12 Months After Burn Accident, in Relation to Texture, Redness, Growth of Hair and Pigmentation, Based on Blinded Photo Evaluation</title>
        <time_frame>3 and 12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Likert Scale Rating of Tolerance (Evaluated by Both the Investigators and Patients)</title>
        <description>By direct comparison of the separate simultaneous treatments for the two wound halves, patients and investigators, respectively, are asked to provide their opinion on the tolerance of Oleogel-S10 Versus Standard of Care on a questionnaire with a 5-point graded visual analogue scale</description>
        <time_frame>2 to 3 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Data: Systemic Presence/Concentration of Betulin in Blood Plasma Samples</title>
        <time_frame>2 to 3 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbial Colonization of the Wound Halves</title>
        <time_frame>2 to 3 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Adverse Events</title>
        <time_frame>2 to 3 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 0 (start of treatment) till end of treatment (Day 21 or earlier if full wound closure was achieved earlier, or later, if the investigator decided to change medication and/or treatment due to unsatisfying wound closure after Day 21).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Entire Study Population - Systemic AEs</title>
          <description>All patients treated with Oleogel-S10 and Octenilin® wound gel. Systemic AEs which are not localized to the wound application site are reported under this arm.</description>
        </group>
        <group group_id="E2">
          <title>Oleogel-S10 Localized AE</title>
          <description>All patients treated with Oleogel-S10 and Octenilin® wound gel. Application site reactions which occurred only at the Oleogel-S10 wound half are reported under this arm.</description>
        </group>
        <group group_id="E3">
          <title>Octenilin Localized AE</title>
          <description>All patients treated with Oleogel-S10 and Octenilin® wound gel. Application site reactions which occurred only at the Octenilin® wound half are reported under this arm.</description>
        </group>
        <group group_id="E4">
          <title>Localized AE Both Wound Halves</title>
          <description>All patients treated with Oleogel-S10 and Octenilin® wound gel. Application site reactions which occurred at both the Octenilin® wound half and Oleogel-S10 wound half in one patient are reported under this arm.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (15.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Condition aggravated</sub_title>
                <description>Further deepening of burn wound</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tonsil cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication requires approval of the sponsor without specification of an embargo time period.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of pharmaceutical development</name_or_title>
      <organization>Birken AG</organization>
      <phone>+49 7233 97490</phone>
      <email>t.zahn@birken.eu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

